Targeting aging cells to improve treatment for pancreatic cancer
Targeting cellular senescense in pancreatic cancer
This study is looking at how getting rid of certain old cells in the body might help make pancreatic cancer treatments work better, and it’s inviting patients to join trials to see if this new method is safe and effective.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Translational Genomics Research Inst NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project ID | NIH-11113721 on NIH RePORTER |
What this research studies
This research investigates how targeting cellular senescence, a process where cells stop dividing, can affect pancreatic cancer treatment. It focuses on the role of senescent cells in creating a tumor-friendly environment that hinders effective therapy. By using a specific antibody to eliminate these senescent cells, the study aims to enhance the effectiveness of standard chemotherapy and immune therapies. Patients may be involved in trials to assess the safety and efficacy of this new approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are undergoing standard cancer treatments.
Not a fit: Patients with early-stage pancreatic cancer or those not receiving standard therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting cellular senescence in other cancer types, suggesting potential for success in this novel approach for pancreatic cancer.
Where this research is happening
Phoenix, United States
- Translational Genomics Research Inst — Phoenix, United States (Active)
Researchers
- Principal investigator: Han, Haiyong — Translational Genomics Research Inst
- Study coordinator: Han, Haiyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.